<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065074</url>
  </required_header>
  <id_info>
    <org_study_id>FX006-2019-017</org_study_id>
    <nct_id>NCT04065074</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip</brief_title>
  <official_title>A Single-arm, Open-label Study to Evaluate a Procedure for Intra-articular (IA) Injection of FX006 in Patients With Osteoarthritis (OA) of the Hip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flexion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flexion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, single-arm, open-label study of FX006 in patients with hip OA. A
      maximum number of approximately 30 patients may be enrolled in this protocol. All enrolled
      patients will receive a single intra-articular (IA) injection of FX006.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, single-arm, open-label study in patients with hip OA to evaluate a
      procedure for intra-articular injection of FX006 in patients with hip OA. A maximum number of
      approximately 30 patients may be enrolled in this protocol.

      All enrolled patients will receive a single intra-articular (IA) injection on Day 1 and be
      followed for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">October 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful study drug administration</measure>
    <time_frame>Day 1</time_frame>
    <description>Successful study drug administration, defined as Injector reporting complete study drug administration and volume administered</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>FX006 32 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular (IA) injection of FX006 32 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FX006 32 mg</intervention_name>
    <description>Extended-release 32 mg FX006 IA injection</description>
    <arm_group_label>FX006 32 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Patients 40 to 80 years of age, inclusive, on the day of randomization (Day 1)

          -  Body Mass Index (BMI) ≤ 40 kg/m2

          -  Has a documented clinical diagnosis of unilateral or bilateral hip OA for at least six
             months

          -  Kellgren-Lawrence (KL) Grade 2 or 3 in the index hip as confirmed by local read of
             X-ray obtained during Screening or ≤ 6 months of Screening visit

          -  Has clinically significant pain in the index hip

        Exclusion Criteria:

          -  Has a history of hypersensitivity to triamcinolone acetonide, PLGA or lidocaine

          -  Is receiving anticoagulants (including warfarin, dabigatran, rivaroxaban, apixaban or
             low molecular weight heparin), ritonavir or cobicistat

          -  Has had any previous surgery on the index hip

          -  Presence of surgical hardware or other foreign body in the index hip

          -  Has a history of infection of the index hip

          -  Has a diagnosis of other disorders in the index hip that can cause pain

          -  Has received any intra-articular injection in the index hip of corticosteroids,
             investigational (including FX006) or marketed (including Zilretta®) within the 3
             months prior to Screening

          -  Has had trauma to the index hip in the past 3 months requiring immobilization

          -  Has a history or evidence of active or latent systemic fungal or mycobacterial
             infection (including tuberculosis), or of ocular herpes simplex

          -  Has within the past 3 months received corticosteroids by mouth, or by parenteral
             injection. Multiple courses or chronic intermittent use of inhaled, intranasal, or
             topical steroids is also exclusionary. Single courses of 14 days or less by those
             routes are permitted

          -  Has, at screening, or any time prior to day of scheduled injection (Day 1), clinical
             suspicion of local or systemic infection, including any infection in the index leg.

          -  Has a history of or active significant concomitant illness (known or suspected)

          -  Any bacterial or viral infection requiring parental antibiotics within 4 weeks of Day
             1 or oral antibiotics within 2 weeks of Day 1

          -  Is a woman who is pregnant, nursing, lactating, or plans to become pregnant during the
             study

          -  Is a man who plans to conceive during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Kelley</last_name>
    <role>Study Director</role>
    <affiliation>Flexion Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Noble Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biosolutions Clinical Research Center</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dream Team Clinical Research</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Hip</keyword>
  <keyword>Intra-articular</keyword>
  <keyword>Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

